Concert Pharmaceuticals
99 Hayden Avenue
Suite 500
Lexington
Massachusetts
02421
United States
Tel: 781-860-0045
Website: http://www.concertpharma.com/
Email: info@concertpharma.com
310 articles about Concert Pharmaceuticals
-
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
5/23/2022
Concert Pharmaceuticals, Inc. today announced positive topline results from its recently completed Phase 3 clinical trial, THRIVE-AA1.
-
Several biopharma companies are opening the week with positive clinical trial news. Read on for updates from Cytokinetics, Concert Pharmaceuticals, Idorsia and Seagen.
-
Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
5/5/2022
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2022.
-
Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022
4/28/2022
Concert Pharmaceuticals, Inc. announced that it will report its financial results for the first quarter of 2022, on Thursday, May 5, 2022, before the U.S. financial markets open.
-
Concert Pharmaceuticals Reports 2021 Financial Results and Provides Company Update
3/3/2022
Concert Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2021.
-
Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022
2/24/2022
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the fourth quarter of 2021, on Thursday, March 3, 2022, before the U.S. financial markets open.
-
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
1/4/2022
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment in THRIVE-AA2, the second Phase 3 clinical trial to evaluate the efficacy and safety of CTP‑543, an oral Janus kinase (JAK) inhibitor, in adult patients with moderate to severe alopecia areata.
-
Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference
1/3/2022
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.
-
Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences
11/11/2021
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a virtual fireside chat at The Jefferies London Healthcare Conference.
-
Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
11/9/2021
Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
-
Concert Pharmaceuticals Announces $65 Million Financing
11/4/2021
Concert Pharmaceuticals, Inc. announced that it has entered into an agreement with BVF Partners L.P. and RA Capital Management to raise gross proceeds of $65 million.
-
The proceeds will be used to advance the development of their ePLC platform, treatment for chronic Hepatitis B, and a novel class of anti-cancer therapies.
-
Concert Pharmaceuticals to Report Third Quarter 2021 Results on November 9, 2021
11/2/2021
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2021, on Tuesday, November 9, 2021, before the U.S. financial markets open.
-
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
10/25/2021
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment in THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP‑543, an oral Janus kinase (JAK) inhibitor, in adult patients with moderate to severe alopecia areata.
-
Concert Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021
9/3/2021
Concert Pharmaceuticals, Inc. announced that it will participate virtually at the following upcoming investor conferences.
-
Concert Pharmaceuticals Reports Second Quarter 2021 Financial Results
8/5/2021
Concert Pharmaceuticals, Inc. reported financial results for the second quarter of 2021.
-
Concert Pharmaceuticals to Report Second Quarter 2021 Results on August 5, 2021
7/29/2021
Concert Pharmaceuticals, Inc. announced that it will report its financial results for the second quarter of 2021, on Thursday, August 5, 2021, before the U.S. financial markets open.
-
Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit
7/1/2021
Concert Pharmaceuticals, Inc. will present an update from its ongoing open label, long-term extension study of the investigational medicine CTP-543 in patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss.
-
Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
5/27/2021
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA2, the second planned Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata.
-
Concert Pharmaceuticals to Present at Upcoming Investor Conferences - May 26, 2021
5/26/2021
Concert Pharmaceuticals, Inc. announced that it will participate at the following upcoming virtual investor conferences